-
Analyst Opinions
NewAI Compute – How Chips Drive Next Industrial Leap
AI Chips Trend Analysis Report Overview GlobalData's "AI Compute: How Chips Drive Next Industrial Leap," innovation radar report explores the transformative impact of semiconductor chip innovations, particularly AI chips, across various industries such as healthcare, telecom, and energy & utilities. The report illuminates how advanced chips are enhancing computational power, enabling improved analytics, and driving automation. By reshaping industrial processes, these technologies are boosting efficiency and fostering innovation. The “AI Compute” report provides strategic insights to help businesses capitalize on...
-
Sector Analysis
NewCell and Gene Therapies in CNS Disorders – Disease Overview, Treatment Options and Future Market Assessment
Cell and Gene Therapies in CNS Disorders Market Report Overview The cell and gene therapies (CGT) sales in central nervous system (CNS) disorders was $1.5 billion in 2023. It will experience significant growth, achieving a CAGR of more than 42% during the forecast period. Gene therapies will dominate the CGT market in CNS disorders because of strong players such as Sarepta Therapeutics and Novartis with marketed products Elevidys and Zolgensma, respectively. Cell and Gene Therapies in CNS Disorders Market Outlook...
-
Product Insights
NewLikelihood of Approval Analysis for Status Epilepticus
Overview How likely is it that the drugs in Status Epilepticus will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Status Epilepticus Overview Status epilepticus is an emergency neurological condition where seizures...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NX-5948 in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NX-5948 in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NX-5948 in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NX-5948 in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NX-5948 in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NX-5948 in Refractory Chronic Lymphocytic Leukemia (CLL) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Brexanolone in Post-Traumatic Stress Disorder (PTSD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Brexanolone in Post-Traumatic Stress Disorder (PTSD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Brexanolone in Post-Traumatic Stress Disorder (PTSD) Drug Details: Brexanolone (Zulresso)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Brexanolone in Alcohol Dependence
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Brexanolone in Alcohol Dependence report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Brexanolone in Alcohol Dependence Drug Details: Brexanolone (Zulresso) is a mixture of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Berubicin Hydrochloride in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Berubicin Hydrochloride in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Berubicin Hydrochloride in Recurrent Glioblastoma Multiforme (GBM) Drug Details:...
-
Product Insights
NewNet Present Value Model: Annexon Inc’s ANX-005
Empower your strategies with our Net Present Value Model: Annexon Inc's ANX-005 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Paxalisib in Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Paxalisib in Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Paxalisib in Glioblastoma Multiforme (GBM) Drug Details: Paxalisib is under development...